Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap®
Ascendis Pharma (ASND) Moves 9.9% Higher: Will This Strength Last?
Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026
Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism
Touchstone Mid Cap Growth Fund Q1 2026 Portfolio Review
5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism
Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026
Ascendis Pharma: Rare Endocrine Compounder Entering Growth Phase (Initiating Buy)
Ascendis Pharma A/S (ASND) Q1 2026 Earnings Call Transcript
Ascendis Pharma Reports First Quarter 2026 Financial Results
New 2-Year Data from Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged ≥5 Years
Ascendis to Report First Quarter 2026 Financial Results and Provide Business Update on May 7, 2026
Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028
Assetmark Inc. Has $1.83 Million Stake in Ascendis Pharma A/S $ASND
Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq
Ascendis Pharma to List Ordinary Shares Directly on Nasdaq
New Data from Week 52 of the Ongoing COACH Trial Showed that TransCon® hGH Accelerated TransCon® CNP's Benefits Beyond Linear Growth in Children with Achondroplasia
Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States
Braun Stacey Associates Inc. Buys 25,148 Shares of Ascendis Pharma A/S $ASND
Allspring Global Investments Holdings LLC Has $40.02 Million Stock Position in Ascendis Pharma A/S $ASND
Ascendis Pharma A/S (NASDAQ:ASND) Share Price Crosses Above Fifty Day Moving Average – Should You Sell?
New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52
Bamco Inc. NY Makes New $1.11 Million Investment in Ascendis Pharma A/S $ASND
New Two-Year Data from Pivotal ApproaCH Trial Showing Durable Benefits of TransCon® CNP (Navepegritide) in Children with Achondroplasia Shared at ACMG 2026
Ally Bridge Group NY LLC Acquires Shares of 51,080 Ascendis Pharma A/S $ASND
Invesco Main Street Mid Cap Fund Q4 2025 Portfolio Activity
Barometer Capital Management Inc. Buys 2,900 Shares of Ascendis Pharma A/S $ASND
Ascendis Pharma A/S (NASDAQ:ASND) Receives Average Rating of “Moderate Buy” from Brokerages
Ascendis Pharma A/S (ASND) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Ascendis Pharma: Yuviwel Approved Despite Legal Challenges
American Century Companies Inc. Buys 13,797 Shares of Ascendis Pharma A/S $ASND
Ascendis Pharma A/S (ASND) Discusses FDA Approval and Commercial Launch Plans for YUVIWEL Transcript
Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference
Ascendis Wins FDA Approval For Rare Disease Therapy
Ascendis wins U.S. approval for therapy for children with dwarfism
FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older
Artisan Partners Limited Partnership Has $739.75 Million Stock Position in Ascendis Pharma A/S $ASND
Ascendis Pharma FY 2025 Results: More Than A Takeover Story
Ascendis Pharma A/S (ASND) Q4 2025 Earnings Call Transcript
Ascendis Pharma Reports Fourth Quarter and Full-Year 2025 Financial Results
Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026
HARBOR CAPITAL ADVISORS, INC. Sells 269 Shares of Ascendis Pharma AS (ASND)
Ascendis Pharma A/S (NASDAQ:ASND) Given Consensus Rating of “Buy” by Brokerages
Ascendis Pharma (ASND) Surges 3.0%: Is This an Indication of Further Gains?
Ascendis Pharma A/S (ASND) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference
Ascendis Pharma A/S (ASND) Discusses Week 52 Topline Results From COACH Trial Evaluating TransCon CNP and Growth Hormone in Achondroplasia Transcript
Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH)
Ascendis Pharma to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Braun Stacey Associates Inc. Makes New $18.68 Million Investment in Ascendis Pharma A/S $ASND